The board will oversee the new Patient Access and Pricing Committee, which will be chaired by Papa himself and include Valeant employees, doctors and scientists, according to a statement Thursday.
Papa took over this week after Valeant shook up the board and pledged better oversight of management. His arrival followed months of turmoil at Valeant, which has become an emblem of high pharmaceutical costs in the U.S. and is being investigated for buying the rights to old, inexpensive drugs and then significantly raising their prices.
0 thoughts on “Valeant Forms Committee to Oversee Drug Prices Under New CEO”
Comments are closed.